Cargando…

First description of revertant mosaicism in familial platelet disorder with predisposition to acute myelogenous leukemia: correlation with the clinical phenotype

Detalles Bibliográficos
Autores principales:	Glembotsky, Ana C., Oyarzún, Cecilia P. Marin, De Luca, Geraldine, Marzac, Christophe, Auger, Nathalie, Goette, Nora P., Marta, Rosana F., Raslova, Hana, Heller, Paula G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556663/ https://www.ncbi.nlm.nih.gov/pubmed/33054100 http://dx.doi.org/10.3324/haematol.2020.253070

Ejemplares similares

Downregulation of TREM-like transcript-1 and collagen receptor α2 subunit, two novel RUNX1-targets, contributes to platelet dysfunction in familial platelet disorder with predisposition to acute myelogenous leukemia
por: Glembotsky, Ana C., et al.
Publicado: (2019)

Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia
por: Marín Oyarzún, Cecilia P., et al.
Publicado: (2020)

Revertant Mosaicism in Epidermolysis Bullosa
por: Meyer-Mueller, Cameron, et al.
Publicado: (2022)

Platelet Apoptosis in Adult Immune Thrombocytopenia: Insights into the Mechanism of Damage Triggered by Auto-Antibodies
por: Goette, Nora P., et al.
Publicado: (2016)

Familial platelet disorders with a predisposition to acute myelogenous leukaemia: a RUNX1 update
por: Rossini, J, et al.
Publicado: (2012)

Revertant somatic mosaicism as a cause of cancer
por: Inaba, Toshiya, et al.
Publicado: (2021)

A "late-but-fitter revertant cell" explains the high frequency of revertant mosaicism in epidermolysis bullosa
por: van den Akker, Peter C., et al.
Publicado: (2018)

Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia
por: Grodzielski, Matías, et al.
Publicado: (2019)

Publisher Correction: Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia
por: Grodzielski, Matías, et al.
Publicado: (2020)

A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation
por: Glembotsky, Ana C, et al.
Publicado: (2021)

Somatic recombination underlies frequent revertant mosaicism in loricrin keratoderma
por: Suzuki, Shotaro, et al.
Publicado: (2019)

Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms
por: Marin Oyarzún, Cecilia P., et al.
Publicado: (2019)

Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies
por: Azzollini, Jacopo, et al.
Publicado: (2017)

Revertant Mosaicism in Genodermatoses: Natural Gene Therapy Right before Your Eyes
por: van den Akker, Peter C., et al.
Publicado: (2022)

Genetic predisposition to mosaic Y chromosome loss in blood
por: Thompson, Deborah J., et al.
Publicado: (2019)

Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms
por: Marin Oyarzún, Cecilia P., et al.
Publicado: (2016)

Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre‐leukaemic clone resulting in T2‐ALL and AML‐M0
por: Manchev, Vladimir T., et al.
Publicado: (2016)

Will It Revert to Pageantry and Burlesque?
Publicado: (1920)

Challenges in Gene Therapy for Somatic Reverted Mosaicism in X-Linked Combined Immunodeficiency by CRISPR/Cas9 and Prime Editing
por: Hou, Yujuan, et al.
Publicado: (2022)

Genetic Predisposition to Mosaic Chromosomal Loss Is Associated With Functional Outcome After Ischemic Stroke
por: Johansson, Malin, et al.
Publicado: (2021)

Revertant mosaicism repairs skin lesions in a patient with keratitis-ichthyosis-deafness syndrome by second-site mutations in connexin 26
por: Gudmundsson, Sanna, et al.
Publicado: (2017)

Myelogenic Leukaemia
Publicado: (1915)

High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis
por: De Luca, Geraldine, et al.
Publicado: (2023)

ATRT-21. Contribution of germline mosaic alterations of SMARCB1 in rhabdoid tumor predisposition syndrome
por: Masliah-Planchon, Julien, et al.
Publicado: (2022)

Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis
por: Cacic, Daniel, et al.
Publicado: (2021)

Immunotherapy for Acute Myelogenous Leukaemia
por: Powles, R. L., et al.
Publicado: (1973)

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2011)

Evaluating Descriptive Metrics of the Human Cone Mosaic
por: Cooper, Robert F., et al.
Publicado: (2016)

zfishbook: connecting you to a world of zebrafish revertible mutants
por: Clark, Karl J., et al.
Publicado: (2012)

Oxygen nanobubbles revert hypoxia by methylation programming
por: Bhandari, Pushpak N., et al.
Publicado: (2017)

Reverting Immune Suppression to Enhance Cancer Immunotherapy
por: Guerrouahen, Bella S., et al.
Publicado: (2020)

Germline RUNX1 Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML
por: Duployez, Nicolas, et al.
Publicado: (2019)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Myelogenous Leukæmia and Its Treatment
por: Debove,
Publicado: (1910)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

Applications of Microarray Technology to Acute Myelogenous Leukemia
por: Goswami, Rashmi S., et al.
Publicado: (2008)

Childhood neuroendocrine tumours: a descriptive study revealing clues for genetic predisposition
por: Diets, I J, et al.
Publicado: (2017)

Human Platelets Effectively Kill K‐562 Cells, a Chronic Myelogenic Leukemia Cell Line, in vitro
por: Sagawa, Terutaka, et al.
Publicado: (1990)

A gain‐of‐function filamin A mutation in mouse platelets induces thrombus instability
por: Adam, Frédéric, et al.
Publicado: (2022)

Small and Innovative Molecules as New Strategy to Revert MDR
por: Zinzi, Laura, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bd3ol28d4bclrj6udolt972edu